Nektar Therapeutics: Full Focus on the Billion-Dollar Market of Immunology

Nektar Therapeutics generates its revenue not from selling its own medications, but from the research of active substances and their subsequent profitable licensing to global pharmaceutical giants. With its main active ingredient REZPEG, the company aims at the targeted regulation of the immune system, tackling huge growth markets such as the treatment of atopic dermatitis and alopecia areata. Thanks to a liquidity reserve of over $1 billion, the expensive clinical research is fully financed well into 2028, drastically minimizing existential...